European Primary Care Cardiovascular Society
A randomized, non-inferiority trial showed comparable HbA1c reductions with an intermittent energy restricted diet compared to a continuous energy restricted diet in adult overweight and obese T2DM patients.
EPCCS 2018 Three professors discuss how best to measure blood pressure, when to call it hypertension, and once hypertension is diagnosed, what BP target to aim for, based on the latest scientific insights.
A subanalysis of the NAVIGATOR-trial showed a significant association between physical activity and reduced risk of the development of diabetes in patients at high CVD risk, independent of gender.
The US Preventive Services Task Force (USPSTF) found evidence that adding the non-traditional risk factors ABI, hsCRP and CAC could slightly improve current CVD risk assessment, but the clinical meaning is unknown.
An explorative study compared the timepoint at which outcome curves separate among 17 statin and 7 non-statin trials. Results suggest that futility should not be declared too early in trials.
A post hoc analysis of a randomized trial showed reduced CVD risk after rosuvastatin therapy with and without candestartan/hydrochlorothiazide, regardless of the number of healthy lifestyle factors.
The Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC) has updated its recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease.
A Cochrane meta-analysis suggests little or no effect of increased intake (dietary or supplementation) of the omega-3 fatty acids ALA and LCn3 on CVD and mortality in adults.
Download the meeting impression of this PACE symposium during EuroPrevent 2018, that considered how to apply novel outcome data with GLP-1 RA to clinical practice.
This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
This is a summary of presentation given by prof. Grobbee, in which he discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
